Cargando…
Efficacy and safety of apatinib combined with whole-brain radiation therapy with a simultaneous integrated boost for brain metastases from non-small cell lung cancer: a multicenter retrospective study
BACKGROUND: Brain metastases (BMs) develop in 20–65% of non-small cell lung cancer (NSCLC) patients and are associated with a poor prognosis. Apatinib, a tyrosine kinase inhibitor (TKI) that selectively inhibits the vascular endothelial growth factor receptor 2, is safe and significantly prolongs th...
Autores principales: | Ma, Jia, Bi, Jianping, Tuo, Xiulin, Pi, Guoliang, Li, Ying, Li, Yanping, Zeng, Fanyu, Gong, Hongyun, Hu, Desheng, Han, Guang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902115/ https://www.ncbi.nlm.nih.gov/pubmed/35280489 http://dx.doi.org/10.21037/jtd-22-96 |
Ejemplares similares
-
Application of piecewise VMAT technique to whole-brain radiotherapy with simultaneous integrated boost for multiple metastases
por: Xu, Yuan, et al.
Publicado: (2022) -
The First Survival Score for Patients Treated with Whole-Brain Radiotherapy Plus Simultaneous Integrated Boost for Brain Metastases
por: Rades, Dirk, et al.
Publicado: (2023) -
Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Xu, Jianping, et al.
Publicado: (2020) -
Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases
por: Ying, Xiaofang, et al.
Publicado: (2020) -
Dosimetric evaluation of four whole brain radiation therapy approaches with hippocampus and inner ear avoidance and simultaneous integrated boost for limited brain metastases
por: Jiang, Aijun, et al.
Publicado: (2019)